Готові списки джерел за темами / Prognosis factor

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Добірка наукової літератури з теми "Prognosis factor"

Автор: Grafiati

Опубліковано: 29 березня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Prognosis factor".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Prognosis factor"

Riley, Richard D., Jill A. Hayden, Ewout W. Steyerberg, Karel G. M. Moons, Keith Abrams, Panayiotis A. Kyzas, Núria Malats, et al. "Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research." PLoS Medicine 10, no. 2 (February 5, 2013): e1001380. http://dx.doi.org/10.1371/journal.pmed.1001380.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Yamagishi, Yuko, and Susumu Kusunoki. "The prognosis and prognostic factor of Guillain-Barré Syndrome." Rinsho Shinkeigaku 60, no. 4 (2020): 247–52. http://dx.doi.org/10.5692/clinicalneurol.cn-001398.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zhu, Aoxuan, Yangyang Dong, Xingchen Li, Yiqin Wang, and Jianliu Wang. "Rationality of the FIGO2023 staging for early-stage endometrial cancer, compared with the FIGO2009 staging." Gynecology and Obstetrics Clinical Medicine 4, no. 1 (April 2024): e000016. http://dx.doi.org/10.1136/gocm-2024-000016.

Повний текст джерела

Анотація:

ObjectiveThe International Federation of Gynecology and Obstetrics (FIGO) released a new staging for endometrial cancer (EC), which revised the FIGO2009 staging to include histopathological and molecular features. The purpose of this study was to validate the prognostic accuracy of the new staging and discuss its clinical applicability.MethodsIn this single-centre retrospective study, 540 patients with primary surgically treated early-stage EC were enrolled and staged according to FIGO2009/2023. Kaplan-Meier survival analysis was used to compare for prognostic differentiation. Cox regression was used to identify potential prognostic indicators.ResultsA total of 81 patients underwent staging shifts, all stage elevation. The prognosis difference between new stages I and II was more significant. The new staging was more predictive of death postoperatively. Lesion maximum diameter (LMD) was one of the independent risk factors associated with prognosis. Taking LMD=5.70 cm as the cut-off value could further differentiate patients with divergent prognoses within FIGO2023 stage IIC.ConclusionFIGO2023 staging demonstrated greater prognostic accuracy. In addition, LMD may be another critical factor affecting prognosis.

Стилі APA, Harvard, Vancouver, ISO та ін.

Tomiyasu, Shinjiro, Keita Sakamoto, Mitsuhiro Inoue, Masayoshi Iizaka, Nobuyuki Ozaki, Kei Horino, Hiroshi Takamori, Masahiko Hirota, and Hideo Baba. "Prognostic factor of distal bile duct cancer (DBDC) and ampullary cancer (AC) after pancreatoduodenectomy." Journal of Clinical Oncology 35, no. 4_suppl (February 1, 2017): 333. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.333.

Повний текст джерела

Анотація:

333 Background: Ampullay cancer (AC) is relatively good prognosis in the biliary tract cancer. Such as LN metastasis, pancreatic invasion is a prognostic factor in AC. On the other hand, Distal bile duct cancer (DBDC) is somewhat good prognosis in the biliary tract cancer. Such as ductal resection margin positive is a prognostic factor in DBDC. There are few papers considered to both difference. Therefore, we conducted this study to examine the difference of AC and DBDC. Methods: To evaluate Cancer-Specific Survival (CaSS), Recurrence-Free Survival (RFS) and prognostic factors after pancreatoduodenectomy (including pylorus-preserving pancreatoduodenectomy: PPPD, subtotal stomach-preserving pancreatoduodenectomy: SSPPD) based on a series of 80 patients of AC and 36 patients of DBDC from 1996 to 2015. We reviewed and analyzed the clinicopathologic data, recurrence and survival. Results: Five years CaSS and RFS of AC were 72.3% and 72.5%. In univariate analysis, pancreatic invasion, R1or R2 resection, duodenal invasion and lymph node metastasis are significantly poor prognosis. In multivariate analysis, pancreatic invasion and R1or R2 resection are poor prognostic factors (pancreatic invasion, p = 0.0012, hazard ratio (HR) 5.65 [confidence interval (CI) 1.92-19.5 95%], R1or R2 resection, p = 0.0043, HR 6.22 [CI 1.68-40.2 95%]). On the other hand, five years CaSS and RFS of DBDC were 35.8% and 46.8%. In univariate analysis, pancreatic invasion (+) ≥ 5 mm in depth, and duodenal invasion are significantly poor prognosis. In multivariate analysis, duodenal invasion is the only poor prognostic factors (p = 0.0227, HR 2.90 [CI 1.16-7.39 95%]). Conclusions: DBDC is considerable poor prognosis compared with AC. Lymph node metastasis is not prognostic factor depends on D2 LN dissection in AC, than pancreatic invasion. Cancer cells invaded pancreatic parenchyma in AC; pancreatic invasion may be the most important prognostic factor by biology-like pancreatic cancer. Duodenal invasion in DBDC was prognostic factor reflects the degree of development of the cancer beyond pancreatic parenchyma. Further clinicopathological and biological studies are needed to confirm our findings.

Стилі APA, Harvard, Vancouver, ISO та ін.

Wei, Yingxin, Ge Chen, Lei You, and Yupei Zhao. "Krüppel-like factor 8 is a potential prognostic factor for pancreatic cancer." Chinese Medical Journal 127, no. 5 (March 5, 2014): 856–59. http://dx.doi.org/10.3760/cma.j.issn.0366-6999.20130674.

Повний текст джерела

Анотація:

Background Pancreatic cancer is a lethal disease that is often diagnosed at an advanced stage. There is a lack of information to predict the prognosis of pancreatic cancer. Krüppel-like factor (KLF) 8 has been found to be deregulated in multiple cancers, and its high expression was correlated with poor prognosis. However, so far, no information was reported about the expression of KLF8 in pancreatic cancer. In the present study, we investigated, possibly for the first time, the expression of KLF8 in pancreatic cancer samples and analyzed its correlation with clinical parameters and overall survival (OS) rate. Methods We used immunohistochemical staining to detect KLF8 in 68 samples from patients who underwent surgery and its correlation with the clinicopathological characteristics. We used Kaplan-Meier curve to analyze the relationship between KLF8 expression and the OS time. Univariate analysis was performed in addition to multivariate hazard models with clinicopathological features to assess KLF8 as an independent prognostic factor. Results KLF8 was present in the cytoplasm of pancreatic cancer cells and 52.9% of the 68 cases had positive expression. KLF8 expression was not associated with sex, age, tumor location, lymph node stage, and metastasis stage, but was associated with tumor stage (P=0.04). Kaplan-Meier method demonstrated that patients with negative expression of KLF8 had a better prognosis. In univariate and multivariate models, KLF8 was a significant predictor of OS in pancreatic cancer. Conclusion Our results revealed that KLF8 may be a potential prognostic factor for pancreatic cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

Tomiyasu, Shinjiro, Eri Oda, Hiroshi Tanaka, Shinji Ishikawa, Hiroki Sugita, Tetsumasa Arita, Yasushi Yagi, et al. "Prognostic factor of carcinoma of the ampulla of vater after surgery." Journal of Clinical Oncology 33, no. 3_suppl (January 20, 2015): 270. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.270.

Повний текст джерела

Анотація:

270 Background: General rules for biliary tract cancer in Japan were revised and Stage of biliary tract cancer was compliant with the seventh UICC. Carcinoma of the Ampulla Vater (CAV) is relatively good prognosis among the biliary tract cancer, such as lymph node metastasis, pancreatic invasion and perineural invasion has been reported to be prognostic factors. We investigated the validity of TNM-Stage by examining the prognostic factors from the outcome of resection experienced. Methods: To evaluate prognostic factors after surgery based on a series of 70 patients of CAV from 1996 to 2014. Twenty-eight patients received pancreatoduodenectomy (PD), 25 patients received pylorus-preserving pancreatoduodenectomy (PPPD) and 17 patients received subtotal stomach-preserving pancreatoduodenectomy (SSPPD). We reviewed and analyzed the clinicopathologic data, surgical outcomes, recurrence and survival. Results: Actuarial disease-specific survival (DSS) was 65 % at five years. In univariate analysis, pancreatic invasion, lymph node metastasis and duodenal invasion are significantly poor prognosis. In multivariate analysis, pancreatic invasion is the only poor prognostic factor (p = 0.0023, hazard ratio (HR) 5.31 [confidence interval (CI) 1.77-18.9 95%]); lymph node metastasis and duodenal invasion are not significantly different (p = 0.0672 and 0.8769, respectively). Also, in the study of relapse risk factors, pancreatic invasion and lymph node metastasis are significantly different. In TNM-Stage II, those of T3N0, 1 are poor prognosis than T1, 2N1 (p = 0.0334). Conclusions: Pancreatic invasion is an independent poor prognostic and recurrence risk factor. The Stage of Japanese Society of Biliary Surgery has reflect prognosis than TNM-Stage in carcinoma of the Ampulla Vater.

Стилі APA, Harvard, Vancouver, ISO та ін.

Zhou, Lili, Lin Mu, Wenyan Jiang, and Qi Yang. "QPRT Acts as an Independent Prognostic Factor in Invasive Breast Cancer." Journal of Oncology 2022 (February 24, 2022): 1–12. http://dx.doi.org/10.1155/2022/6548644.

Повний текст джерела

Анотація:

Background. Quinolinic acid phosphoribosyltransferase (QPRT) is a rate-limiting enzyme that encodes the uronic acid pathway, which is involved in cell cycle progression and cancer cell metabolism. Some studies have demonstrated the progrowth effect of QPRT on breast cancer (BRCA) tumour cells, but its mechanism of action requires further exploration. Methods. We investigated the expression of QPRT and the prognosis of patients with different tumours by performing a pan-cancer analysis of QPRT. Prognostic values for overall survival (OS) were determined using uni- and multivariate Cox proportional hazard analyses. The prognostic survival of patients with a different pathological staging of BRCA and with QPRT high and low expression was also analysed. We also explored the relevant pathways by which QPRT affected BRCA tumorigenesis by gene set enrichment analysis (GSEA) and western blotting. The impact of QPRT on the PI3K/Akt pathway was also evaluated. Results. Pan-cancer analysis revealed significant QPRT expression in pan-cancer and correlated with prognosis in most tumour patients. QPRT was also highly expressed in BRCA when patients had poor prognoses, and its expression was associated with different pathological BRCA subtypes. GSEA revealed an association between BRCA progression and the cell cycle and the phosphatidylinositol 3-kinase (PI3K)/Akt signalling pathway, and this association was confirmed by western blotting. Conclusion. QPRT is highly expressed in breast cancer and particularly in HER2 breast cancer. Upregulated QPRT expression is an independent predictor of breast cancer prognosis and promotes breast cancer progression by activating the PI3K/Akt signalling pathway.

Стилі APA, Harvard, Vancouver, ISO та ін.

Liu, Qi, Yuji Li, Ming Dong, Fanmin Kong, and Qi Dong. "Gastrointestinal Bleeding Is an Independent Risk Factor for Poor Prognosis in GIST Patients." BioMed Research International 2017 (2017): 1–6. http://dx.doi.org/10.1155/2017/7152406.

Повний текст джерела

Анотація:

A retrospective analysis of prognosis of GIST was used to assess the prognostic effects of hemorrhage of digestive tract induced by mucosal invasion of primary gastrointestinal stromal tumors and related mechanisms. The conclusion is that GISTs with gastrointestinal hemorrhage are more likely to recur, which indicates poor prognosis. Therefore, gastrointestinal hemorrhage may be used as a significant indicator to assess the prognosis of patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

Kojima, Osamu, Yuuji Yoshioka, Hiroshi Minato, Ryouji Iiduka, Eigo Otsuji, Masataka Shimotsuma, Hiroki Taniguchi, et al. "Prognostic Factor of Gastric Carcinoma-Usefulness for Prognostic Factor and Improvement of Prognosis in Patients with Gastric Cancer." Japanese Journal of Gastroenterological Surgery 26, no. 10 (1993): 2499–502. http://dx.doi.org/10.5833/jjgs.26.2499.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Yared, Jean Abou, Theodore Girinsky, Serge Koscielny, Vincent Ribrag, Patrice Carde, Suzanna Ceapa, and Christophe Ferme. "Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF] and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with Non-Hodgkin Lymphoma." Blood 112, no. 11 (November 16, 2008): 1768. http://dx.doi.org/10.1182/blood.v112.11.1768.1768.

Повний текст джерела

Анотація:

Abstract Introduction: Tumor angiogenesis is gaining importance in hematological malignancies; it is balanced by many known and unknown positive and negative angiogenic factors. However, studies related to the prognostic significance of angiogenic factors and lymphoproliferative diseases are limited compared to solid tumors. This is a single institution study evaluating the prognostic impact of serum Endostatin, VEGF, and bFGF in non-Hodgkin’s lymphoma (NHL). Patients and methods: Pretreatment serum level of Endostatin (S-Endostatin), VEGF (S-VEGF), and bFGF (S-bFGF) were measured by Enzyme-Linked Immunoabsorbant Assay (ELISA) on 136 NHL patients: 82 patients (60%) had aggressive NHL (diffuse large B cell lymphoma [DLBCL] or other aggressive non-DLBCL) and 54 patients (40%) had indolent lymphomas (follicular lymphoma [FL] or other indolent non-FL). For each angiogenic factor, univariate progression-free survival (PFS) and overall survival (OS) analyses were performed according to the quartiles of the distribution of serum level values. Each of the analyses was aimed to detect a trend between prognosis and the serum level of the angiogenic factor. Eight prognostic groups were defined according to the type of NHL and the prognostic indexes (International Prognostic Index [IPI] for DLBCL and aggressive non-DLBCL, and Follicular International Prognostic Index [FLIPI] for FL). Survival analyses stratified on the prognostic group were used to test the independent prognostic value of each angiogenic factor. Survival curves were compared with logrank tests. Distributions of serum level values were compared with Kruskal-Wallis tests. The median follow-up was 78 months. Results: Pretreatment angiogenic serum levels were not significantly different between all categories of NHL, except for VEGF level, which was slightly higher in the aggressive group compared to the indolent group (666 pg/ml vs. 465 pg/ml; p=0.03). Low S-Endostatin and high S-VEGF at diagnosis were associated with poor PFS (p=0.002 and p=10−4 respectively) and poor OS (p=0.04 and p=10−6 respectively). Patients with S-Endostatin within the lowest quartile had only 29% PFS and 49% OS in contrast to a 67% PFS and 82% OS among patients with Endostatin within the highest quartile. Similarly, patients with S-VEGF within the highest quartile had only 20% PFS and 26% OS in contrast to a 70% PFS and 85% OS among patients with VEGF within the lowest quartile. The VEGF/Endostatin ratio was used to combine the results from S-VEGF and S-Endostatin. The 4 groups corresponding to the quartiles of the distribution of VEGF/Endostatin ratio had different OS and PFS (p<10−6 for both); PFS and OS were respectively 15% and 16% for patients from the highest quartile VEGF/Endostatin ratio and 79% and 84% for those from the lowest quartile Figure 1. The independent prognostic impact of S-Endostatin, S-VEGF and VEGF/Endostatin ratio remained significant on PFS (p=0.0003, p=0.001 and p<10−6 respectively) and OS (p=0.01, p=10−4 and p<10−6 respectively) after stratification on the prognostic group. We did not find any relation between pretreatment S-bFGF and prognosis in our patients. Conclusion: Our results showed that pretreatment serum levels of VEGF and Endostatin are significantly related to outcome in NHL patients; the higher the VEGF/Endostatin ratio is, the poorer the prognosis. A better understanding of angiogenesis in lymphoproliferative diseases is mandatory in order to develop new anti-angiogenic targeted therapeutic agents that can change the outcome of these patients. Figure Figure

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Prognosis factor"

KUHN, Elisabetta. "GATA3 IS AN ADJUNCT PROGNOSTIC FACTOR IN BREAST CANCER PATIENTS, ESPECIALLY WITH LESS AGGRESSIVE DISEASE." Doctoral thesis, Università degli studi di Ferrara, 2018. http://hdl.handle.net/11392/2488158.

Повний текст джерела

Анотація:

Recently, GATA3 has emerged as a sensitive lineage-specific marker for breast cancers (BCs) and their metastases. Interestingly, GATA3 expression is positively correlated with estrogen receptor (ER) expression. Moreover, some studies have investigated GATA3 as a prognostic marker in BC patients, with conflicting findings. Thus, we undertook the current study to evaluate the expression of GATA3 by immunohistochemistry in a large series of BCs with long-term follow-up and its prognostic value. A total of 702 consecutive primary invasive BCs were diagnosed and resected between 1989 and 1993 in our institution. All BCs were arranged in tissue microarrays, immunostained for ER, progesterone receptor (PR), Ki-67, HER2, p53, and GATA3. ER, PR, Ki-67, p53, and GATA3 were scored as the percentage of positive BC cells. Moreover, p53 was considered as with mutant pattern, if completely negative or with at least 60% of BC cell nuclei showing intense positivity, or with wild-type pattern, when showed a variable weak-moderate positivity in <60% of BC cells. HER2 was scored according to 2013 ASCO/CAP guidelines. Clinico-pathological data (including patient age, tumor histology, pathologic stage, grading, and follow-up data) were retrospectively collected. Statistical analyses with a p-value <0.05 were considered significant. GATA3 was evaluable in 608 (87%) of 702 cases and resulted positive (≥1%) in 413 (68%) cases and negative (<1%) in 195 (32%) cases, with a GATA3 median percentage score of 50% (range 0%-100%). GATA3 positivity correlated significantly with lower histological grade (p<0.0001), size (p=0.0463), and stage (p=0.0049). Among the biological factors, GATA3 expression was associated with ER+ (p<0.0001), PR+ (p<0.0001), HER2- (p=0.373), and p53 wild-type pattern (p<0.0001). In our patients with a median follow-up of 183 months, after adjusting for age, GATA3 positivity correlated significantly with a better overall survival (hazard ratio [HR] 0.70, p=0.001), and its predictive power was retained in multivariate analysis. Moreover, GATA3 expression correlated with a better overall survival in BC patients with less aggressive characteristics: histologic grade 1 and 2 (HR 0.69, p=0.003), pT1-2 (HR 0.68, p=0.001), pN0 (HR 0.65, p=0.003), stage I-II (HR 0.65, p<0.0001), ER+ (HR 0.77, p=0.046), PR+ (HR 0.74, p=0.022), Ki-67<20% (HR 0.72, p=0.0008), HER2- (HR 0.64, p<0.0001), and in BC with wild-type p53 immunohistochemical pattern (HR 0.71, p=0.011). Among molecular subtypes, lack of GATA3 correlated with a worse overall survival only in luminal B BC. On the other hand, the predictive power of GATA3 in disease-free survival outcome was significant only at 48-month follow-up (HR 0.63, p=0.001), but was not independent of other variables in multivariate analysis. Our findings indicate that GATA3 is a positive prognostic marker in BC patients, especially in patients with biologically less aggressive BC.
Il fattore di trascrizione GATA3 è usato comunemente come marker immunoistochimico specifico di primitivita’ mammaria e uroteliale. Nel carcinoma della mammella l’espressione di GATA3 correla positivamente con quella dei recettori degli estrogeni (ER) e alcuni studi hanno investigato GATA3 come fattore prognostico, con risultati inconcludenti. In questo studio abbiamo valutato l’espressione di GATA3, mediante colorazione immunoistochimica, e il suo valore prognostico in un’ampia casistica di carcinomi infiltranti della mammella con follow-up lungo (con mediana di 15 anni). Abbiamo analizzato 702 casi consecutivi di carcinoma infiltrante primitivo della mammella diagnosticati presso il Servizio di Anatomia Patologica dell’Azienda Ospedaliero-Universitaria di Ferrara fra il 1989 e il 1993. Tutti i casi sono stati campionati per allestire dei tissue microarrays. Sezioni consecutive di tissue microarrays sono state immunocolorate per la valutazione di: ER, recettori del progesterone (PR), ki-67, HER2, p53 e GATA3. Tutti questi marcatori sono stati valutati come percentuale di cellule tumorali positive. A p53 è stato attribuito un pattern mutato, in caso di completa negatività o positività intensa pari o superiore al 60%, o un pattern “wild-type”, in caso di positività’ inferiore al 60%. HER2 è stato valutato in accordo con le linee guida ASCO/CAP del 2013. Le informazioni clinico-patologiche (età, istotipo, stadio patologico, grado e follow-up) sono state raccolte retrospettivamente. Le analisi statistiche con un p-value <0.05 sono state considerate significative. GATA3 è stato valutabile in 608 (87%) dei 702 casi ed è risultato positivo (≥1%) in 413 (68%) casi e negativo (<1%) in 195 (32%) casi, con una percentuale mediana di positività del 50% (intervallo 0%-100%). La positività di GATA3 correlava significativamente con basso grado istologico (p<0.0001), minor dimensione (p=0.0463) e basso stadio (p=0.0049). Rispetto ai fattori biologici, l’espressione di GATA3 era associata a ER positivi (p<0.0001), PR positivi (p<0.0001), HER2 negativo (p=0.373) e p53 con pattern wild-type (p<0.0001). Nelle nostre pazienti, con una mediana di follow-up pari a 183 mesi, dopo aver aggiustato per età, la positività di GATA3 correlava significativamente con una migliore overall survival (hazard ratio [HR] 0.70, p=0.001), e il potere predittivo era mantenuto in analisi mutivariata. Inoltre, l’espressione di GATA3 correlava con una miglior overall survival in pazienti con caratteristiche meno aggressive del carcinoma mammario: grado 1 e 2 (HR 0.69, p=0.003), pT1-2 (HR 0.68, p=0.001), pN0 (HR 0.65, p=0.003), stadio I-II (HR 0.65, p<0.0001), ER+ (HR 0.77, p=0.046), PR+ (HR 0.74, p=0.022), ki-67<20% (HR 0.72, p=0.0008), HER2- (0.64, p<0.0001) e pattern immunoistochimico di p53 wild-type (HR 0.71, p=0.011). Riguardo ai sottotipi molecolari, l’assenza di GATA3 correlava con una peggior overall survival solo nei carcinomi luminali B. D’altra parte, il potere predittivo di GATA3 per la disease-free survival e’ risultato significativo solo per follow-up pari a 48 mesi (HR 0.63, p=0.001), ma non si è dimostrato indipendente dalle altre variabili nell’analisi multivariata. I nostri risultati indicano che GATA3 è un marker prognostico positivo indipendente nelle pazienti con carcinoma mammario, specialmente con malattia biologicamente meno aggressiva.

Стилі APA, Harvard, Vancouver, ISO та ін.

Rowlands, Mari-Anne Elin. "The Insulin-Like Growth Factor System in Prostate Cancer Aetiology and Prognosis." Thesis, University of Bristol, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.525471.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Johnson, Lisa Godefroy. "The relationship of obesity-related metabolic hormones and prognosis in young women with breast cancer /." Thesis, Connect to this title online; UW restricted, 2003. http://hdl.handle.net/1773/10874.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Poon, Tung-ping Ronnie, and 潘冬平. "Prognostic significance of circulating vascular endothlial [sic] growth factor in patients with hepatocellular carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B36922249.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ishigami, Shunichi. "Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer." Kyoto University, 1999. http://hdl.handle.net/2433/181241.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Amdani, Siti Nornadhirah. "The oocyte-activation factor, phospholipase C zeta (PLCζ) : clinical prognosis, diagnosis, and treatment of oocyte activation deficiency". Thesis, University of Oxford, 2018. https://ora.ox.ac.uk/objects/uuid:af4c4f98-497a-4666-9eec-a46bb579dd59.

Повний текст джерела

Анотація:

Oocyte activation deficiency (OAD) is an infertile condition observed in patients who have experienced recurrent total fertilisation failure (TFF) following intracytoplasmic sperm injection treatment. This condition was considered to be an idiopathic factor for a long time but strong clinical evidence now suggests that dysfunctional forms of phospholipase C zeta (PLCζ) may be predominant causative factors for OAD. Genetic contribution has played a role in patients suspected of having OAD, as four PLCζ exonic mutations have been discovered and characterised as being the cause of infertility. In this study, a novel nonsense mutation, PLCζK322Stop, was identified in the PLCζ XY-linker region of Patient LR. This variant results in the truncation of approximately half of PLCζ, therefore was non-functional when activity was tested. Patient LR, which also exhibited a previously reported mutation, PLCζH233L, may suggest that the patient is sub-fertile, as opposed to being infertile, as initially expected. Although research has purely focused upon the coding regions of PLCζ, it was obvious that our knowledge of PLCζ regulatory elements remain very limited. Next generation sequencing (NGS) was therefore employed to detect variants in the non-coding regions of PLCζ, promoter and introns, which may have resulted in the observed phenotypic diversity of PLCζ expression in fertile and infertile patients. As a result of mapping failure, an alternative approach was considered to identify variants within human PLCζ, and this involved using the single nucleotide polymorphism (SNP) database. Over 2500 SNPs were localised in the intronic regions of PLCζ and thus, it could be speculated that these variants may help elucidate the wide variation of PLCζ expression reported. Additionally, two particular patients with TFF (79 and 107) were investigated in this study to identify an association with PLCζ and their infertile state. For Patient 79, multiple PLCζ immunofluorescence analysis was performed and a significant improvement in PLCζ expression was observed one year after his first investigation. This may have been the result of an external factor, which influenced protein expression. As for Patient 107, a novel substitution mutation, PLCζV193E, was identified and was predicted to affect PLCζ stability and folding. There is global interest to create a safer and alternative OAD therapy, namely a human recombinant PLCζ protein (hrPLCζ). The first method, using a bacterial cell line resulted in successful purification and identification but the product proved to be inactive following mouse oocyte microinjection. The second method involved production of a mammalian-expressed hrPLCζ, which was successfully purified and identified but due to time restrictions, could not be tested for functionality. Concurrently, the findings in this thesis have reinforced the association between PLCζ and OAD, and provided improved options for the diagnosis and treatment of OAD.

Стилі APA, Harvard, Vancouver, ISO та ін.

Durkan, Garrett Christopher. "Matrix metalloproteinase-1 and -9 and tissue inhibitor of metalloproteinase-1 in bladder cancer : pathophysiological significance and relationship to epidermal growth factor receptor expression." Thesis, University of Newcastle Upon Tyne, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.369832.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Dreilich, Martin. "Predictive Factors in Esophageal Carcinoma." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-6831.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ekdahl, Christer. "Infective Endocarditis : aspects of pathophysiology, epidemiology, management and prognosis." Doctoral thesis, Linköping : Department of Clinical and Experimental Medicine, Linköping University, 2008. http://www.bibl.liu.se/liupubl/disp/disp2008/med1017s.pdf.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bello, Rodríguez Irene. "Trasplante pulmonar: la obesidad del receptor como factor pronóstico." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/399331.

Повний текст джерела

Анотація:

La Disfunción Primaria del Injerto (DPI) en el trasplante pulmonar es un daño agudo que se manifiesta clínicamente en las primeras 72 horas postoperatorias. Se caracteriza por un daño alveolar inespecífico, baja compliance pulmonar e hipoxemia. La incidencia de DPI varia entre 11% y el 57% en función de las diferentes series. La DPI es una importante causa de morbimortalidad después del trasplante pulmonar. Es la principal causa de mortalidad en los 30 días postrasplante (24,1%). Durante el primer año es la segunda causa de mortalidad (16,6%). La DPI influye en los resultados del trasplante, afectando a los días de ventilación mecánica (LOV), estancia en UCI(LOS), estancia hospitalaria (hLOS), mortalidad a corto plazo e incrementa el riesgo del síndrome de bronquiolitis obliterante (BOS). Un elevado número de factores de riesgo se han asociado al desarrollo de DPI. Se pueden clasificar en tres grupos, los relacionados con el donante, con el receptor y con el periodo perioperatorio. Uno de los factores relacionados es la obesidad del receptor preoperatoria. Varios estudios han mostrado la asociación del IMC>30 Kg/m2 y un LOV, LOS y hLOS prolongado, un incremento de la mortalidad a corto plazo y de la incidencia de BOS. El consenso publicado por la Sociedad Internacional de Trasplante de Corazón y Pulmón (ISHLT) en 2015 considera como contraindicación relativa el IMC preoperatorio del receptor mayor de 30 Kg/m2 y como contraindicación absoluta el IMC>35 Kg/m2. Se han revisado restrospectivamente 348 trasplantes pulmonares realizados entre Enero 2010 y Diciembre 2015. Los pacientes se agruparon por IMC>18 Kg/m2, IMC 18 to 24,9 Kg/m2, IMC 25 to 30 Kg/m2 and IMC >30 Kg/m2. Se usó como definición de DPI la de la ISHLT. El 63,2% de los trasplantados fueron hombres y el 36,8% mujeres. La edad media de los receptores fue de 52,6 años (DE=11,6%). La principal indicación de trasplante fue el grupo de patologías restrictivas (45,5%) y la enfermedad pulmonar obstructiva crónica (EPOC) (32,2%). El 61,21% de los trasplantes fue bilateral. El grupo con IMC<18 Kg/m2 incluía al 8,4% de los receptores, el grupo con IMC 18-25 Kg/m2 el 39,9%, el grupo con IMC 25-30 Kg/m2 el 37,9 y el grupo con IMC >30 Kg/m2 incluía al 14,5% de ellos. La incidencia de DPI fue de 41,28%. El grupo con IMC >30 Kg/m2 tuvo una incidencia mayor de DPI (64,58%, p=0,0006), no se observaron diferencias en el grado ni duración de la DPI. El grupo con IMC >30 Kg/m2 tenía un riesgo incrementado de DPI en el análisis univariante (OR: 3.68, 95% CI: 1,848 – 7,359; P .002) y en el multivariante (OR: 3,371, 95% CI: 1,623 – 7,004; P .001). No se observaron diferencias estadísticamente significativas en LOV, ICU LOS, hLOS, rechazo agudo, infección respiratoria, riesgo incrementado de BOS, tiempo libre de BOS ni en la supervivencia a los 30 días postoperatorios, 90 días postoperatorios, 1 año ni 3 años. Observamos que un IMC >30 Kg/m2 está asociado con un riesgo incrementado de DPI, sin afectar esta asociación a LOV, ICU LOS, hLOS, rechazo agudo, infección respiratoria, riesgo incrementado de BOS, tiempo libre de BOS ni en la supervivencia a los 30 días postoperatorios, 90 días postoperatorios, 1 año ni 3 años. En conclusión, identificamos una asociación entre la obesidad preoperatoria y la DPI. Ésta no afecta a la supervivencia a corto ni medio plazo, así como ni al pronóstico del trasplante pulmonar. Más estudios son necesarios para esclarecer el papel que juega la obesidad preoperatoria del receptor en el trasplante pulmonar.
Primary Graft Dysfunction (PGD) in lung transplant is an acute lung injury that is clinically evident in the first 72 hours after lung transplantation. It’s characterized by nonspecific alveolar damage, poor lung compliance and hypoxemia. The incidence of PGD varies on different series, between 11%-57%. PGD remains responsible for significant early morbidity and mortality after lung transplant. PGD is the main cause of mortality in the first 30 days post transplant (24,1%). It is the second cause of mortality during the first year (16,6%). PGD leads to adverse short-term outcomes, including prolonged length of mechanical ventilation(LOV), ICU length of stay(LOS), hospital length of stay (hLOS), increased cost, short-term mortality and increased risk of bronchiolitis obliterants syndrome (BOS). A number of risk factors associated to PGD’s development have been investigated, but so far, conflicting results have been yielded. These risk factors can be classified into three groups. First those related with the donor, second those related with the recipient and finally those associated with the perioperative period. One of the risk factors related with the recipient is an elevated recipient body mass index (BMI). Several studies have showed an association between recipient obesity and prolonged LOV, LOS, hLOS, increased short-term mortality and increased risk of BOS. A consensus document about the selection criteria for recipients to lung transplant was published in 2015 by The International Society of Heart and Lung transplant (ISHLT). In this consensus the recipient obesity (BMI>30 Kg/m2) is a relative contraindication and a BMI>35 Kg/m2 is an absolute contraindication for lung transplant. We retrospectively reviewed a cohort of 348 recipients of lung transplants performed between January 2010 and December 2015. Patients were divided in 4 groups according to their BMI>18 Kg/m2, BMI 18 to 24,9 Kg/m2, BMI 25 to 30 Kg/m2 and BMI >30 Kg/m2. PGD was defined according to the ISHLT guidelines There were 63,2% male and 36,8% female recipients. Mean recipient age was 52,6 years (SD=11,6%). The main indications for transplantation were Idiopathic pulmonary fibrosis (45.5%) and Emphysema (32.2%). The 61,21% of the procedures were bilateral lung transplants. The group with BMI<18 Kg/m2 included 8,4% of recipients, the group with BMI 18-25 Kg/m2 39,9%, the group with BMI 25-30 Kg/m2 included 37,9% of recipients and BMI>30 Kg/m2 included 14,5% of them. The incidence of PGD was 41,28%. The group with BMI>30 Kg/m2 had an increased incidence of PGD (64,58%, p=0,0006), But differences between grade or time of PGD were not seen. The group group with BMI>30 Kg/m2 had an increased risk of PGD compared with the group with BMI 18-25 Kg/m2 in univariant analysis (OR: 3.68, 95% CI: 1,848 – 7,359; P .002) and multivariant analysis (OR: 3,371, 95% CI: 1,623 – 7,004; P .001). No differences were observed in LOV, ICU LOS, hLOS, acute rejection, respiratory infection, increased risk of BOS, free-time of BOS and in 30d postoperative survival, 90d postoperative survival,1-year and 3-year survival. We observed that a BMI > 30 Kg/m2 is associated with an increased risk of PGD, but this association doesn’t affect LOV, ICU LOS, hLOS, acute rejection, respiratory infection, increased risk of BOS, free-time of BOS and 30d postoperative survival, 90d postoperative survival, 1-year and 3-year survival. In conclusion, we identified an association between preoperative obesity and PGD This association does not impact survival and outcomes after lung transplantation. Further studies are required to clarify the role that preoperative obesity plays in lung transplant.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Книги з теми "Prognosis factor"

Gospodarowicz, M. K., D. E. Henson, R. V. P. Hutter, B. O'Sullivan, L. H. Sobin, and Ch Wittekind, eds. Prognostic Factors in Cancer. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2003. http://dx.doi.org/10.1002/0471463736.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hermanek, P., Mary K. Gospodarowicz, D. E. Henson, R. V. P. Hutter, and L. H. Sobin, eds. Prognostic Factors in Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-79395-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

K, Gospodarowicz M., and International Union against Cancer, eds. Prognostic factors in cancer. 2nd ed. New York: Wiley-Liss, 2001.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

K, Gospodarowicz M., O'Sullivan B, and Sobin L. H, eds. Prognostic factors in cancer. 3rd ed. Hoboken: Wiley, 2006.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

K, Gospodarowicz M., and International Union Against Cancer, eds. Prognostic factors in cancer. 2nd ed. New York: Wiley-Liss, 2001.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Paul, Hermanek, and International Union against Cancer, eds. Prognostic factors in cancer. Berlin: Springer, 1995.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ulrik, Charlotte Suppli. Prognosis and risk factors for bronchial asthma. København: Lægeforeningens Forlag, 1998.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Hortobagyi, Gabriel N. Stage III breast cancer: Prognostic factors and therapy. Bethesda, MD (Bldg. 82, Rm. 103, Bethesda 20892): U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1988.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Th, Büchner, ed. Acute leukemias IV: Prognostic factors and treatment strategies. Berlin: Springer-Verlag, 1994.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

M, Thompson Alastair, ed. Prognostic and predictive factors in breast cancer. 2nd ed. London: Informa Healthcare, 2008.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Частини книг з теми "Prognosis factor"

Nakamura, Hideji, Kenya Yoshida, and Yasuhiko Tomita. "Hepatocellular Carcinoma: Prognosis Using Hepatoma-Derived Growth Factor Immunohistochemistry." In Liver Cancer, 333–42. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-1-4020-9804-8_26.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Grotzer, Michael A., Tarek Shalaby, and Alexandre Arcaro. "Central Nervous System Atypical Teratoid/Rhabdoid Tumors: Role of Insulin-Like Growth Factor I Receptor." In Methods of Cancer Diagnosis, Therapy, and Prognosis, 353–64. Dordrecht: Springer Netherlands, 2010. http://dx.doi.org/10.1007/978-90-481-8665-5_27.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Meding, Birgitta. "Atopy as a Factor in the Prognosis of Hand Dermatitis." In Kanerva’s Occupational Dermatology, 1–7. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-40221-5_102-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Meding, Birgitta. "Atopy as a Factor in the Prognosis of Hand Dermatitis." In Kanerva’s Occupational Dermatology, 1533–39. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-68617-2_102.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Meding, Birgitta. "Atopy as a Factor in the Prognosis of Hand Dermatitis." In Kanerva's Occupational Dermatology, 1113–16. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-02035-3_102.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Gospodarowicz, M. K., and B. O’Sullivan. "Prognosis and Prognostic Factors." In Germ Cell Tumours V, 63–75. London: Springer London, 2002. http://dx.doi.org/10.1007/978-1-4471-3281-3_15.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Frasci, Giuseppe, Giuseppe D’Aiuto, Giovanni Iodice, Renato Thomas, Massimiliano D’Aiuto, and Giuseppe Comella. "Estrogen Receptor-Negative and HER-2/neu-Positive Locally Advanced Breast Carcinoma: Therapy with Paclitaxel and Granulocyte-Colony Stimulating Factor." In Methods of Cancer Diagnosis, Therapy and Prognosis, 415–32. Dordrecht: Springer Netherlands, 2008. http://dx.doi.org/10.1007/978-1-4020-8369-3_30.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Shah, N. G., and T. I. Trivedi. "Early Stage Oral Squamous Cell Carcinoma: Use of Signal Transducer and Activator of Transcription 3 as a Risk Factor for Poor Diagnosis." In Methods of Cancer Diagnosis, Therapy, and Prognosis, 237–53. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-3186-0_17.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Finn, Stephen P., John J. O’Leary, and Orla M. Sheils. "Papillary Thyroid Carcinoma: Detection of Copy Gain of Platelet Derived Growth Factor B Using Array Comparative Genomic Hybridization in Combination with Laser Capture Microdissection." In Methods of Cancer Diagnosis, Therapy, and Prognosis, 387–98. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-3186-0_26.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bhalla, Parinishtha, Anukriti Verma, Bhawna Rathi, Shivani Sharda, and Pallavi Somvanshi. "Exploring Molecular Signatures in Spondyloarthritis: A Step Towards Early Diagnosis." In Proceedings of the Conference BioSangam 2022: Emerging Trends in Biotechnology (BIOSANGAM 2022), 142–55. Dordrecht: Atlantis Press International BV, 2022. http://dx.doi.org/10.2991/978-94-6463-020-6_15.

Повний текст джерела

Анотація:

AbstractSpondyloarthritis is an acute inflammatory disorder of the musculoskeletal system often accompanied by pain, stiffness, bone and tissue damage. It majorly consists of ankylosing spondylitis, psoriatic arthritis and reactive arthritis. It follows a differential diagnosis pattern for demarcation between the spondyloarthritis subtypes and other arthritic subtypes such as rheumatoid arthritis, juvenile arthritis and osteoarthritis due to the heterogeneity causing gradual chronicity and complications. Presence of definite molecular markers can not only improve diagnosis efficiency but also aid in their prognosis and therapy. This study is an attempt to compose a refined list of such unique and common molecular signatures of the considered subtypes, by employing a reductionist approach amalgamating gene retrieval, protein-protein interaction network, functional, pathway, micro-RNA-gene and transcription factor-gene regulatory network analysis. Gene retrieval and protein-protein interaction network analysis resulted in unique and common interacting genes of arthritis subtypes. Functional annotation and pathway analysis found vital functions and pathways unique and common in arthritis subtypes. Furthermore, miRNA-gene and transcription factor-gene interaction networks retrieved unique and common miRNA’s and transcription factors in arthritis subtypes. Furthermore, the study identified important signatures of arthritis subtypes that can serve as markers assisting in prognosis, early diagnosis and personalized treatment of arthritis patients requiring validation via prospective experimental studies.

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Prognosis factor"

Sim, Jae Kyeom, Jee Youn Oh, Kyung Hoon Min, Gyu Young Hur, Sung Yong Lee, Jae Jeong Shim, and Kyung Ho Kang. "Risk factor and prognosis of ventilator-associated event." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.oa4477.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Andrade, Gustavo Moreira, Leonardo Chaves de Oliveira Moraes, Diogo Casagrande Nunes de Souza, Isadora de Sousa Gomes, Marcos Vinícius Milki, and Izabela Ramos Nascimento. "Angiogenesis, heroine, or villain? The expression and significance of vascular endothelial growth factor when dealing with the prognosis of patients with breast cancer." In Brazilian Breast Cancer Symposium 2024, 86. Mastology, 2024. http://dx.doi.org/10.29289/259453942024v34s1086.

Повний текст джерела

Анотація:

Objective: Vascular endothelial growth factor (VEGF) is an important signaling protein that acts in muscle and tissue regeneration and promotes angiogenesis. However, it can help spread the tumor through metastases. Therefore, the objective of this review was to evaluate the expression and significance of VEGF when dealing with the prognosis of patients with breast cancer. Methodology: We comprehensively searched the PubMed database for studies and trials that included expression of VEGF and breast cancer prognosis in their papers. Our systematic review followed the PRISMA statement guidelines. Results: VEGF is a signaling protein and appears to be an effective direct pro-angiogenic factor that increases vascular permeability and promotes neoangiogenesis, playing a crucial role in the development and progression of vascularization and tumor growth. Furthermore, it stimulates the proliferation and migration of endothelial cells in a way that promotes tumor survival, invasion, and metastasis through the inhibition of endothelial cell apoptosis. It also shows a suppressive function in antitumor immune activity by promoting the recruitment and proliferation of immunosuppressive cells such as Treg cells and myeloid-derived suppressor cells. Thus, in several types of breast cancers, such as locally advanced breast cancer, the edematous inflammatory form, and subtypes, such as triple-negative breast cancer, increased VEGF levels were observed resulting from secretion by cancer cells and a significant correlation between inflammatory cytokines and VEGF due to the activation of signaling pathways in the tumor microenvironment. In turn, in breast cancer metastases, mainly bone, lung, brain, and lymph nodes, there was high expression of VEGF due to its role in the recruitment of tumor-associated macrophages (TAMs) and metastasis-associated macrophages, contributing to cancer severity and worse prognosis. Conclusion: Therefore, the use of VEGF as a prognostic biomarker and therapeutic target is relevant, as factors related to angiogenesis may have significant prognostic value for patients with breast cancer and/or metastatic disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

Laban, Simon, Romain Remark, Christian Idel, Julika Ribbat-Idel, Rosemarie Krupar, Andreas Schröck, Niklas Klümper, et al. "Combining CD3 density and PD-L1 expression into one prognostic factor identifies patients with an exceptional prognosis." In 95th Annual Meeting German Society of Oto-Rhino-Laryngology, Head and Neck Surgery e. V., Bonn. Georg Thieme Verlag KG, 2024. http://dx.doi.org/10.1055/s-0044-1784752.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ramalho Fernandes, Filipa, Filipa Carriço, Filomena Luís, Rita Gomes, Alcina Tavares, Adelino Amaral, and Luís Ferreira. "Influence of Thyroid Transcription Factor 1 expression in prognosis of lung adenocarcinoma." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa4216.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Wegman-Ostrosky, Talia, Ernesto Soto-Reyes, Silvia Vidal-Millan, Sonia Mejia, José Sánchez-Corona, and Luis A. Herrera. "Abstract 594: AGT mutations as a prognosis factor in patients with astrocytoma." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-594.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Calero-Diaz, Hugo, David Chushig-Muzo, Himar Fabelo, Inmaculada Mora-Jimenez, Conceicao Granja, and Cristina Soguero-Ruiz. "Data-driven cardiovascular risk prediction and prognosis factor identification in diabetic patients." In 2022 IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI). IEEE, 2022. http://dx.doi.org/10.1109/bhi56158.2022.9926871.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Aidar, Osvaldo de Alcântara Braga. "CHANGES IN KI67 AS A PROGNOSTIC FACTOR AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2086.

Повний текст джерела

Анотація:

Objective: Patients with tumors that require neoadjuvant chemotherapy may have a better prognosis when there is a good response to therapy. Those who do not have a complete response are the target of studies that aim to improve overall survival, and for that, factors that guide additional therapy should be identified. This study aims to evaluate the prognostic influence of Ki67 and its variation between the values analyzed before neoadjuvant chemotherapy and after surgery in patients with residual disease. Methods: The medical records of 126 patients treated between 2008 and 2013 at CORA/HC-UFG with breast cancer were retrospectively analyzed. Of these, 43 patients with invasive breast carcinoma met the inclusion criteria, and the data were collected on the histological and immunohistochemical types, presence of hormone receptors for invasive breast tumors, in addition to the evaluation of age, stage, and chemotherapy medications used. Ki67 should be evaluated in the material of the diagnostic core biopsy and in the surgical specimen with residual disease after neoadjuvant chemotherapy. The monitoring of events was carried out until the cutoff date of January 1, 2019. Results: The high Ki67 value at diagnosis was related to a worse prognosis, while low values were related to a lower incidence of clinical events (p=0.004). The optimal value found in the receiver operating characteristic curve as a cutoff for high or low values was 25%, with the statistical significance for sensitivity and specificity (p=0.008). There was no statistical significance in event-free survival and overall survival related to the Ki67 variation assessed on biopsy and surgical specimen after neoadjuvant chemotherapy, with p=0.67 and p=0.57, respectively. Conclusion: The high rates of Ki67 at diagnosis are related to worse survival in patients who have undergone neoadjuvant chemotherapy and have residual disease. The variation of its values before and after neoadjuvant chemotherapy cannot be used as a predictive factor to the treatment until there are larger studies, with the standardization of its evaluation.

Стилі APA, Harvard, Vancouver, ISO та ін.

Li, Xiaolin, Xuehui Zhang, Jing Li, Ying Guo, Li Zhao, Minxin Zhang, and Quanxin Qu. "Vaginal expression of IL-6 can be a prognosis factor of cervical intraepithelial neoplasias." In JSGO 2023. Korea: Korean Society of Gynecologic Oncology, 2023. http://dx.doi.org/10.3802/jgo.2023.34.s2.p336.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ribeiro, Laíse Alves, João Victor Monteiro de Camargo, Bruno Buzá Joioso, and Ailton Joioso. "Metabolic syndrome as a risk factor for the development of breast cancer in women and its impact on prognosis." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1086.

Повний текст джерела

Анотація:

Objective: Metabolic syndrome (MS) is a complex metabolic disorder. The aforementioned main components are systemic arterial hypertension, insulin resistance, obesity, and dyslipidemia. Highly acclaimed evidence supports the hypothesis that MS may be associated with breast cancer (BC) development and worse prognosis. The increasing incidence rates of both MS and BC seem to corroborate this theory. This article aims to assess the association between MS and BC development, later diagnosis, and worse prognosis. Methodology: An inclusive literature review was conducted on PubMed and SciELO. Results: First, excess of adipose tissue characteristic of MS not only enhances the expression of pro-inflammatory factors but also increases the aromatization process. The latter is a neuroendocrine change that occurs in adipocytes and leads to greater estrogen synthesis, which increases the risk for the development of BC. It was concluded that MS is an independent risk factor for BC with a relative risk (RR) of 1.75%. MS is also associated with more aggressive and poorer differentiated tumors. Women with MS have higher rates of BC in stages III and IV. Furthermore, hyperinsulinemia and hyperglycemia are directly related to axillary lymph node involvement, high histological grade, and late staging. Moreover, it is known that women diagnosed with both MS and BC have worse oncologic prognosis. The aforesaid is exemplified by the increased recurrences and decreased survival in BC associated with high fasting plasma insulin levels. Additionally, obese women with BC have a worse prognosis and a higher risk of developing a second primary BC. Conclusion: As mentioned above, MS is significantly associated with an increased risk, invasive progression, and adverse outcomes of BC due to neuroendocrine changes, namely, abnormal estrogen levels. It is therefore strongly recommended to adhere to dietary strategies and regular physical activities in order to prevent MS. Consequently, there would be a possibility of reducing the incidence rates of BC.

Стилі APA, Harvard, Vancouver, ISO та ін.

Jebali, Rihab, Sabrine Louhaichi, Ikbel Khalfallah, Sabrine Elfidha, Line Kaabi, Safa Marzouki, Med Ali Kharrat, Jamel Ammar, Besma Hamdi, and Agnès Hamzaoui. "Obesity in patients with COVID-19: is it a predictive factor for a poor prognosis?" In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa806.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Prognosis factor"

Bruno, Francesco, Domenico Arcuri, Francesca Vozzo, Antonio Malvaso, Alberto Montensanto, and Raffaele Maletta. Expression and signaling pathways of Nerve Growth Factor (NGF) and pro-NGF in breast cancer: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0017.

Повний текст джерела

Анотація:

Review question / Objective: This study aims to systematically review and comprehensively summarize the current experimental evidence about the involvement of Nerve Growth Factor (NGF) and pro-NGF signaling pathways in breast cancer. Therefore, the questions are as follows: (1) What is the expression level of NGF, pro-NGF and their receptors in breast cancer? (2) What is the role played by NGF, pro-NGF and their receptors in the pathophysiological mechanisms (i.e., proliferation, apoptosis, angiogenesis, invasion, metastasis) of breast cancer? (3) What is the diagnostic, prognostic and therapeutic potential of NGF, pro-NGF and their receptors in breast cancer? Condition being studied: Breast cancer is a neoplasm of epithelial origin that generally develops in the parts of the breast tissue made up of the glands involved in milk production or in the ducts that connect the glands to the nipple. In women it represents the most frequent cancer as well as the leading cause of cancer death. The incidence of breast cancer is estimated to increase over the years and to reach 3.2 million in 2050, thus representing a health emergency both from a medical and a psychological point of view. Therefore, prevention and early diagnosis of breast cancer appears to be of primary urgency as well as the development of new treatments able to improve its prognosis.

Стилі APA, Harvard, Vancouver, ISO та ін.

Zhao, Hao, Chunhao Liu, Yanlong Li, and Xiaoyi Li. Prognostic factors for survival in differentiated thyroid cancer with pulmonary metastases: a protocol of systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0026.

Повний текст джерела

Анотація:

Pulmonary metastasis (PM) is the most common form of distance metastasis in differentiated thyroid cancer (DTC), which has a poor prognosis. However, the prognostic risk factors are not yet well identified and analyzed. This systematic review and meta-analysis aims to fill this blank though identifying and discussing survival prognostic risk factors systematically for DTC patients with PM. Pulmonary metastasis (PM) is the most common form of distance metastasis in differentiated thyroid cancer (DTC), which has a poor prognosis. However, the prognostic risk factors are not yet well identified and analyzed. This systematic review and metastases aims to fill this blank though identifying and discussing survival prognostic risk factors systematically of DTC patients with PM. Condition being studied: differentiated thyroid cancer with pulmonary metastases.

Стилі APA, Harvard, Vancouver, ISO та ін.

Fan, Junjie, Li Gao, Jing Chen, and Shaoyan Hu. Influence of KIT mutations on prognosis of pediatric patients with core-binding factor acute myeloid leukemia: systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2020. http://dx.doi.org/10.37766/inplasy2020.9.0019.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Neodo, Anna, Fiona Augsburger, Jan Waskowski, Joerg C. Schefold, and Thibaud Spinetti. Monocytic HLA-DR expression and clinical outcomes in adult ICU patients with sepsis – a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0119.

Повний текст джерела

Анотація:

Review question / Objective: The scope of this review was defined using PICOTS framework where 1) population: adult critically ill patients with sepsis or septic shock; 2) index prognostic factor: cell surface protein expression of mHLA-DR in blood; 3) comparative factor: none; 4) outcomes to be predicted: mortality, secondary infections, length of stay, and organ dysfunction score (sequential organ failure assessment [SOFA], multiple organ dysfunction score [MODS], logistic organ dysfunction score [LODS]), composite outcomes where component endpoints consist of at least one of the outcomes stated above (e.g., “adverse outcome” defined as death or secondary infection), 5) timing (of the prediction horizon and the moment of prognosis): any; and 6) setting: ICU. Condition being studied: Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to severe infections. It can further progress to septic shock, which includes hemodynamic failure and increased mortality rates. A recent worldwide epidemiological study estimated 48.9 million sepsis cases and 11 million of sepsis-related deaths (~20% of global deaths in 2017). Although its management has advanced considerably, sepsis remains deadly and challenging to treat. The 28/30-day mortality averages around 25% for sepsis and 38% for septic shock in high-income countries. Current models describe the underlying pathophysiologic mechanisms of sepsis as an interplay between concurrent dysfunctional pro- and anti-inflammatory immune response.

Стилі APA, Harvard, Vancouver, ISO та ін.

Yang, Ming, Youwei Wu, Tao Wang, and Wentao Wang. Iron overload, Infectious Complications and Survival In Liver Transplant Recipients: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0022.

Повний текст джерела

Анотація:

Review question / Objective: Iron overload conditions is a well-established risk factor for infection of pathogens. The possible association of iron overload with infectious complications and prognosis of patients receiving transplants are not well understood. Condition being studied: Liver transplantation often represents a life-saving treatment for an increasing number of patients with end-stage liver disease. With the improvements in surgical techniques, immunosuppression strategies, and post-LT management of complications, the recipient mortality has steadily declined after LT. The survival rates were 83% at 1 year, 71% at 5 years in western countries. However, the use of immunosuppressants increased risk of infections as an adverse effect resulting in severe morbidity. Globally, infection caused by including bacteria, fungus, viruses remain one of the leading causes of morbidity and mortality among transplant recipients. Knowledge of modifiable risk factors and potentially reversible causes is essential to develop targeted preventive strategies.

Стилі APA, Harvard, Vancouver, ISO та ін.

ZHAO, JIE, LIANHUA YE, WEI WANG, YANTAO YANG, ZHENGHAI SHEN, and SUNYIN RAO. Surgical Prognostic Factors of Second Primary Lung Cancer: A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0047.

Повний текст джерела

Анотація:

Review question / Objective: The objective of this study was to explore the effects of different surgical strategies and potential prognostic factors on the prognosis of patients with SPLC through a systematic review and meta-analysis.Prognostic factors included surgical approach, type of SPLC(Synchronous and metachronous),histology,disease-free interval (DFI),tumor size,CT morphology, lymph node metastasis status, smoking status, gender. Condition being studied: With the development of imaging technology and better survival after primary lung cancer, the detection rate of second primary lung cancer (SPLC) has been increasing. At present, the staging and treatment of the second primary lung cancer are still controversial. Although surgery is widely accepted as the main treatment method, there is no unified diagnostic criteria and diagnosis and treatment strategy. The objective of this study was to explore the effects of different surgical strategies and potential prognostic factors on the prognosis of patients with SPLC through a systematic review and meta-analysis.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ouyang, Zhiqiang, Qian Li, Guangrong Zheng, Tengfei Ke, Jun Yang, and Chengde Liao. Radiomics for predicting tumor microenvironment phenotypes in non-small cell lung cance: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0060.

Повний текст джерела

Анотація:

Review question / Objective: Tumor microenvironment (TIME) phenotype is an important factor to affect the response and prognosis of immunotherapy in non-small cell lung cancer (NSCLC). Recently, accumulating studies have noninvasivly perdited the TIME phenotypes of NSCLC by using CT or PET/CT based radiomics. We will conduct this study by means of meta-analysis to eveluate the power and value of CT or PET/CT based radiomics for predicting TIME phenotypes in NSCLC patients. Condition being studied: At present, several recent prospective or retrospective cohort studies and randomized controlled studies have confirmed that CT or PET/CT-based radiomics were the potential tools to predict TIME phenotypes in NSCLC. However, this conclusion is controversial because of the difference of prediction profermance of different studies. The published and unpublished investigations will be included in this study. We will comprehensively evaluate the heterogeneity of these investigations, and the power and value of radiomics for predicting TIME phenotypes.

Стилі APA, Harvard, Vancouver, ISO та ін.

Melbye, Mads. Risk Factors for Breast Cancer and its Prognosis. Fort Belvoir, VA: Defense Technical Information Center, October 1997. http://dx.doi.org/10.21236/ada340845.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Seidman, Jeffery. Prognostic Factors in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 1995. http://dx.doi.org/10.21236/ada299729.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

O'Leary, Timothy J., and Jeffrey D. Seidman. Prognostic Factors in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, March 1997. http://dx.doi.org/10.21236/ada353773.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!